Wuxi Apptec (603259:SSE) written Q&A, August 28, 2025 transcript

Transcript, summary, guidance, and what analysts pressed on from the Wuxi Apptec call on August 28, 2025.

FreeSee Wuxi Apptec's financials in GloomOpen in browser →Jump to the transcript
Held
August 28, 2025
Tone
Confident0.75
Words
1,518
2025 continuing-operations growth
13-17%full year
Continuing-operations backlog
567亿元record; up 37.2%
U.S. production base
by the end of 2026expected use
Singapore API base
in 2027first phase planned
Interim dividend plan
about 1 billion yuanexpected by end-September
Adjusted non-IFRS net profit growth
44.4%first half year over year

Summary

Management framed the call around strong demand and execution, raising its full-year outlook while balancing shareholder returns with global capacity investment.

  • The company emphasized its integrated CRDMO model and continued capacity expansion as the basis for growth.
  • Management said no Biosafety Act proposals had restarted in the 119th U.S. Congress, while continuing to monitor developments.
  • Shareholder returns included completed repurchases and dividends, alongside a new H-share placement to fund global expansion.

Guidance

  • 7%2025 continuing-operations revenue growth 13-17%

What analysts pressed on

  • 01Biosafety legislation: management said no restart proposal had emerged in the 119th Congress and declined to quantify policy impacts.
  • 02Potential customer disruption: management cited strong orders and execution but gave no specific exposure or impact estimate.
  • 03Further Yaoming United share sales: management did not answer directly, saying it would optimize investments and focus on core capacity.
  • 04Future buybacks and dividends: management said it would propose repurchases to the board in due course and maintain stable distributions.
  • 05U.S. manufacturing and geopolitical exposure: management said the facility is expected to enter use by end-2026, without quantifying mitigation effects.

Notable disclosures

  • 37.2%567亿元 continuing-operations backlog was a record, up 37.2% year over year.
  • The 2025 revenue target was raised, with free-cash-flow guidance increased accordingly.
  • The company said its Swiss oral-preparation capacity doubled in 2024.
  • Singapore’s API production base is planned to begin operation in 2027.

Risks raised

  • Potential U.S. policy or geopolitical changes could affect customer confidence or operations, but management provided no quantified impact.
  • The U.S. pharmaceutical production base is still under construction and is expected to enter use only by end-2026.
  • Global capacity expansion competes with shareholder distributions for capital, though management gave no investment-cost guidance.

Tone: Confident 0.75

Management raised full-year targets on strong demand and record backlog, while acknowledging policy uncertainty and emphasizing the need for continued capacity investment.

Who spoke

Company

  • Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC
  • Yang QingExecutive Director, Co-Chief Executive Officer, WUXI APPTEC
  • Shi MingChief Financial Officer, WUXI APPTEC
  • Han MinBoard Secretary, WUXI APPTEC

Full transcript

Analyst questions are marked with a bar. Timestamps are into the recording.

Prepared remarks

ModeratorSSE Roadshow Center

Ladies and gentlemen, investors and netizens, hello! Welcome to WuXi AppTec 2025 Semi-annual Performance Presentation. This activity is sponsored by Wuxi WuXi AppTec New Drug Development Co., Ltd. and supported by the network platform provided by Shanghai Stock Exchange Information Network Co., Ltd. Thank you for your attention and participation. On July 29, Wuxi Yaoming Kangde New Drug Development Co., Ltd. published the Semi-annual Report 2025. Investors can log on the website of Shanghai Stock Exchange (https://www.sse.com.cn/) or this platform (https://roadshow.sseinfo.com/).

View related announcements. In order to facilitate investors to have a more comprehensive and in-depth understanding of the company's operating results and financial situation in the first half of 2025, the company decided to hold the semi-annual performance presentation of WuXi AppTec in 2025. In today's event, the main members of the management of Yaoming Kangde visited the Shanghai Roadshow Center and will communicate with investors. Everyone is welcome to participate actively.

Questions and answers

Investor

What is the company's current dividend and future dividend policy?

Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that since this year, the company has completed the distribution of cash dividends totaling 3.84 billion yuan, including the annual dividend of 2.83 billion yuan in 2024 (maintaining the annual dividend ratio of 30% of the net profit attributable to the parent company) and the special dividend of 1.01 billion yuan in 2025. At the same time, the company announced the first interim dividend plan, totaling about 1 billion yuan, which is expected to be completed by the end of September.

Please pay attention to the company's subsequent announcement on the implementation of the distribution of rights and interests. The Company will maintain an active, sustainable and stable profit distribution policy, and create long-term value for shareholders while continuing to invest in capacity and productivity construction and ensuring the sustainable development of the Company.

Investor

Will the company further reduce its holdings of Yaoming United?

Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that the company will continue to optimize its investment portfolio and focus on the capacity and capacity building of its CRDMO core business.

Investor

What is the current construction situation of the American factory? What are the company's plans for the future geopolitical impact?

Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that the company is currently building a pharmaceutical production base in the United States, which is expected to be put into use by the end of 2026. The company continues to focus on the unique integrated CRDMO business model, implements the strategies of "follow science", "follow customers" and "follow molecules", grasps the certainty of customers'demand for empowerment, promotes the sustained and steady growth of business, efficiently and extremely empowers customers, and is committed to bringing more new and good drugs to patients around the world.

At the same time, the company is accelerating the global layout and capacity building.

Investor

Will the company further expand its chemical business (small molecules) in overseas markets in the future? Whether to maintain a positive view of offshore business, considering that the biosafety bill has not been passed

Yang QingExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that the company has always been adhering to the positioning of the global innovation enabling platform, and is now accelerating the global layout and capacity construction.

The company is expanding the preparation base in Switzerland, and the production capacity of oral preparations has been doubled in 2024; meanwhile, the company is building a preparation production base in the United States, which is expected to be put into use by the end of 2026; and the company is building an API production base in Singapore, and the first phase of the base is planned to be put into operation in 2027.

Investor

Hello, Mr. Chen, what effective measures has the company taken to deal with the Biological Act? Will the follow-up company have a major adjustment? Will it follow the "Foxconn" to "Huawei" model? Thank you!

Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that the company understands that the 118th Congress of the United States has expired in early 2025, during which no relevant proposals of the Biosafety Act have been passed. So far, the 119th Congress of the United States has not made any proposal to restart the legislative process of the bill. The company will continue to pay close attention to legislative developments.

Investor

According to the information learned by the company from the customer side, will the company's business delivery and operation be affected by potential new bills or related policies?

Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that it will continue to focus on its unique integrated, end-to-end CRDMO (contract research, development and manufacturing) business model, seize the certainty of customer demand for empowerment, continuously expand new capabilities and build new capacity, continue to optimize production processes and improve operating efficiency, promote sustained and steady business growth, empower customers efficiently and to the fullest extent, and strive to bring more new and better medicines to patients around the world.

In the first half of 2025, the company achieved revenue of 20.8 billion yuan, of which revenue from continuing operations grew 24.2% year on year, and adjusted non-IFRS net profit grew 44.4% year on year. Orders on hand for continuing operations reached a new historical high of 56.7 billion yuan, up 37.2% year on year. Based on this strong growth momentum and continued highly efficient execution, the company raised its full-year 2025 revenue target to 42.5-43.5 billion yuan, with continuing operations expected to achieve double-digit growth of 13-17%.

It also raised its free cash flow target accordingly to 5-6 billion yuan. The company will continue to focus on building capabilities and expanding scale, continuously improve production and operating efficiency, and create greater value for customers and shareholders.

Investor

Recently, we have seen that Hong Kong stocks have the option of fixed increase and debt-to-equity swap, so will the company consider new repurchase and cancellation?

Shi MingChief Financial Officer, WUXI APPTEC

In response to your question, the Company believes that since the beginning of this year, the Company has completed a total of 2 billion yuan of a share repurchase, and all the repurchased shares will be cancelled; the Company has implemented a total of 5.84 billion yuan of share repurchase and cancellation and cash dividends this year, accounting for more than 60% of the net profit attributable to the parent company in 2024.

In order to accelerate the global layout and capacity construction, the company raised HK $7.65 billion through the public placement of H shares in August this year to support the company's long-term development, serve customers efficiently and perfectly, and ultimately achieve the goal of "making the world no difficult medicine, no difficult disease" and benefit the global patients.

Investor

Does the company consider repurchasing and canceling shares again and increasing shareholder dividends?

Han MinBoard Secretary, WUXI APPTEC

In response to your question, the company believes that in terms of dividends, since 2025, the company has completed the distribution of cash dividends totaling 3.84 billion yuan, including the annual dividend of 2.83 billion yuan in 2024 (maintaining the annual dividend ratio of 30% of the net profit attributable to the parent company) and the special dividend of 1.01 billion yuan in 2025. At the same time, the company announced its first interim dividend plan, totaling about 1 billion yuan, which is expected to be completed by the end of September.

In terms of repurchase, the company has completed a total of 2 billion yuan of A-share repurchase program and cancelled the full amount of repurchased shares. In the future, the Company will continue to implement a proactive, sustainable and stable profit distribution policy, and the management will also propose a repurchase plan to the Board in due course, so as to create long-term value for shareholders while continuing to invest in capacity and production capacity construction and ensuring the sustainable development of the Company.

Han MinBoard Secretary, WUXI APPTEC

Due to time constraints, the WuXi AppTec 2025 Semi-annual Results Presentation has ended. I am very pleased to discuss and communicate with you on the company's industry situation, business situation and other aspects, and sincerely thank all investors for their warm and friendly exchanges and their continuous attention and ardent expectations for WuXi AppTec! After the meeting, investors are welcome to further communicate with us through diversified ways such as investor relations telephone, e-mail and SSE e-interaction.

ModeratorSSE Roadshow Center

Dear investors and netizens, the semi-annual performance presentation of WuXi AppTec 2025 is drawing to a close. We invite guests from listed companies to make concluding remarks.

ModeratorSSE Roadshow Center

This is the successful conclusion of the semi-annual performance presentation of WuXi AppTec in 2025. Thank you for the active participation of investors and netizens. If you have further questions, you can keep communicating with the company through the e interactive platform of Shanghai Stock Exchange. Thank you!

Other Wuxi Apptec earnings calls

  • Q2 2026 earnings call

    Management framed growth as increasingly supported by later-stage molecule progression, rising capacity utilization and operating efficiency.

    Aug 28, 2026Confident0.82
  • written Q&A, August 27, 2026

    Management framed the raised outlook as demand-led pipeline conversion, while emphasizing execution, capacity readiness and resilience amid geopolitical and currency headwinds.

    Aug 28, 2026Positive0.48
  • written Q&A, April 12, 2026

    Management framed growth around CRDMO capacity expansion and operational efficiency, while offering little quantified detail on pricing, capital allocation or customer concentration.

    Apr 13, 2026Mildly positive0.35
  • written Q&A, November 11, 2025

    Management framed durable CRDMO demand and capacity expansion as the growth engine, while emphasizing policy uncertainty and declining to quantify near-term peptide ramp or pricing effects.

    Nov 12, 2025Mildly positive0.35

All Wuxi Apptec transcripts

About this transcript

The call was held in another language and translated. The summary, guidance, analyst focus, and tone are automated and should be checked against the call before being relied on. Names and figures can be misheard. Listen to the replay.